Foundayo vs Wegovy Pill: Which Can UK Patients Get?

Foundayo or Wegovy Pill? What UK Patients Can Actually Get Right Now

For years, the catch with the most effective weight-loss medicines was simple: they came as an injection, and plenty of people quietly decided a weekly jab was not for them. An oral version was always going to shift that calculation.

Now two of them are in the news at the same time, and it is tempting to assume you can just pick whichever sounds better. In the UK, you can't, at least not yet, understanding why is the whole point of this guide.

Start with the fact that decides it

Before any talk of chemistry or trial results, one thing settles the question for most people in Britain today. The Wegovy pill, an oral form of semaglutide, was licensed by the MHRA on 11 June 2026 and can be dispensed on a private prescription^[1].

Foundayo, the name Eli Lilly gives to a drug called orforglipron, has been approved in the United States but not here. No UK pharmacy can lawfully supply it, and that holds true whatever route you try, private included. So read the rest of this with that in mind: one of these tablets is a live option, the other is a preview of what might arrive later.

Two tablets, two very different molecules

On the surface the pair look like siblings. Each is swallowed once a day, each belongs to the GLP-1 class of medicines, and each owes its appeal to the same idea of a tablet in place of a syringe. Look closer, though, and they are built from different blueprints.

The Wegovy pill comes from Novo Nordisk and carries semaglutide, the identical active ingredient found in the Wegovy injection many people will already have heard of.

Its approval in June 2026 was a genuine first, because no weight-loss tablet of any kind had ever been licensed in the UK before it^[1]. For the moment it is a private-prescription medicine for eligible adults, with no NHS funding behind it.

Foundayo starts from a different chemical place. Semaglutide is a peptide, a chain of amino acids that digestion tends to pull apart, which is precisely why the injectable exists.

Orforglipron is a small, non-peptide molecule that comes through the stomach intact. That one design decision is the reason, as you will see shortly, that it arrives without the fussy timing rules the Wegovy pill imposes. Lilly won its US approval on 1 April 2026^[3], and a NICE appraisal is scheduled for 18 November 2026^[6], though none of that counts for much in practice until a UK licence is actually granted.

How a GLP-1 tablet quiets your appetite

Both drugs lean on the same piece of biology. After a meal, your gut puts out a hormone whose job is to tell the brain you have had enough. GLP-1 medicines stand in for that hormone, so the fullness signal turns up sooner and lingers longer.

In daily life that tends to feel like three connected things: less hunger between meals, a stomach that empties more slowly so smaller portions keep you going, and a lower-calorie diet that stops feeling like an hourly test of willpower.

Foundayo vs Wegovy: the trial numbers and an honest caveat about them

It is tempting to lay the two studies side by side and declare a winner. Resist that, because they were never built to be compared: different patients, different doses, different durations, different statistics.

With that caution in place, here is what each one showed. In the OASIS 4 study, adults on the 25 mg Wegovy tablet lost an average of about 13.6% of their body weight over 64 weeks^[2].

In a separate trial, ATTAIN-1, adults on the top 36 mg dose of orforglipron lost roughly 11.2% over 72 weeks, and around six in ten of those on that dose shed at least a tenth of their starting weight^[5]. Placed next to each other the Wegovy number looks a shade higher, but that difference is not a true head-to-head outcome.

The more balanced, accurate conclusion: both deliver serious, double-digit average loss for a pill, and deciding which fits a particular person is a prescriber's call, not a league-table result.

How do Foundayo and Wegovy work differently: what taking each one is actually like

This is where the practical gap really shows. The Wegovy pill asks for a bit of discipline. You take it whole first thing, on a stomach that has been empty for at least eight hours, with no more than a small mouthful of water, then wait a full half hour before you eat, drink anything else or take other medication. These steps are not suggestions; without them the tablet will not absorb as it should, so they are part of the treatment itself.

Orforglipron does away with all of that. Because it survives the gut, it can be taken whenever suits your day, with food or without, water or none^[4].

The single habit the two share is a gradual build: both begin at a low dose and step up slowly, which keeps early side effects in check.

Sharing a drug class means the two share a safety picture in broad strokes. The everyday complaints are digestive: nausea, vomiting, diarrhoea and constipation, usually mild to moderate and most common in the opening weeks or just after a dose increase.

The rarer problems carry more weight. Both come with the class risks of pancreatitis and gallbladder trouble, and in January 2026 the MHRA strengthened its guidance on acute pancreatitis for GLP-1 medicines, telling anyone with severe, persistent stomach pain that may spread to the back, sometimes with nausea and vomiting, to seek urgent medical help^[7].

In the United States, orforglipron's label additionally carries a boxed warning about a possible risk of thyroid C-cell tumours, a caution attached to several medicines in this family^[4].

Neither tablet is suitable in pregnancy or breastfeeding, neither is for children, and neither is right for every adult, which is exactly why a Bliss clinician has to assess you before you start. If you ever suspect a medicine has caused a side effect, you can report it through the MHRA Yellow Card scheme. ^[8]

Foundayo vs Wegovy at a glance

The table below gathers the key differences in one place. Treat the weight-loss figures as a rough guide, since they come from separate trials rather than a direct contest.

How to choose between Wegovy and Foundayo

For a UK reader choosing today, the decision more or less makes itself: the Wegovy pill is the only one you can actually obtain. Foundayo may earn a place alongside it later, if and when it clears a UK licence, but it is not worth chasing in the meantime.

Any website claiming to sell orforglipron to British customers right now should set off alarm bells, because medicines from unregulated sellers can be counterfeit or contaminated, and no saving is worth that risk.

Whichever you end up on, a tablet is only ever part of the work. These medicines do their best alongside changes to how you eat, how you move and the support you have around you, and they are prescription-only for good reason.

If you think one might help, the sensible next step is a proper assessment. You can talk to your GP or pharmacist, or begin an online consultation at Bliss, where a prescriber can take you through what is genuinely available and whether it suits you.